Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca's Hudson Optimistic On Return To Growth In 2017

Jan 25 2016

• By Jessica Merrill

Related Content

AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate

Apr 23 2012

Is <em>Brilinta</em> The Treatment To Keep AstraZeneca’s Lifeblood Flowing?

Apr 01 2013

AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance

Dec 20 2013

With Anoro, GSK Takes A Two-Step Toward Bolstering Respiratory

Dec 23 2013

AZ Centers Pearl As The Jewel Of Its Respiratory Franchise

Jun 10 2013

AstraZeneca’s <em>Iressa</em>, Now Resurrected, Faces Daunting U.S. EGFR Market

Jul 20 2015

AstraZeneca Diabetes Combo Needs More Clinical Data, FDA Says

Oct 16 2015

Related Companies

AstraZeneca PLC

Pfizer Inc.

Roche Holding AG

Novartis AG

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Acerta Pharma BV

Bristol Myers Squibb Company

Eli Lilly and Company

Boehringer Ingelheim GmbH

CVS Caremark

GSK plc

Novartis AG

Pearl Therapeutics, Inc.

Takeda Pharmaceutical Co. Ltd.

Forest Laboratories, Inc.

Nycomed GmbH

ZS Pharma

Actelion Pharmaceuticals Ltd.

Relypsa, Inc.

Ardea Biosciences, Inc.

Additional Topics

Business Strategies Strategy Launches Pricing Strategies Deals BioPharmaceutical

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window